- Home
- MRK vs TGTX Comparison
MRK vs TGTX Comparison
Compare MRK & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRK
- TGTX
- Stock Information
- Founded
- MRK 2000
- TGTX 1993
- Country
- MRK United States
- TGTX United States
- Employees
- MRK N/A
- TGTX N/A
- Industry
- MRK Biotechnology: Pharmaceutical Preparations
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MRK Health Care
- TGTX Health Care
- Exchange
- MRK Nasdaq
- TGTX Nasdaq
- Market Cap
- MRK 218.8B
- TGTX 5.5B
- IPO Year
- MRK N/A
- TGTX 1995
- Fundamental
- Price
- MRK $83.50
- TGTX $33.77
- Analyst Decision
- MRK Buy
- TGTX Strong Buy
- Analyst Count
- MRK 15
- TGTX 6
- Target Price
- MRK $105.14
- TGTX $47.50
- AVG Volume (30 Days)
- MRK 10.0M
- TGTX 1.5M
- Earning Date
- MRK 10-30-2025
- TGTX 11-04-2025
- Dividend Yield
- MRK 3.74%
- TGTX N/A
- EPS Growth
- MRK 20.41
- TGTX N/A
- EPS
- MRK 6.49
- TGTX 0.36
- Revenue
- MRK $63,616,000,000.00
- TGTX $454,069,000.00
- Revenue This Year
- MRK $1.76
- TGTX $82.13
- Revenue Next Year
- MRK $5.11
- TGTX $49.01
- P/E Ratio
- MRK $13.35
- TGTX $93.64
- Revenue Growth
- MRK 1.82
- TGTX 30.96
- 52 Week Low
- MRK $73.31
- TGTX $22.92
- 52 Week High
- MRK $105.11
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- MRK 42.56
- TGTX 48.97
- Support Level
- MRK $86.91
- TGTX $32.81
- Resistance Level
- MRK $88.30
- TGTX $35.33
- Average True Range (ATR)
- MRK 1.43
- TGTX 1.18
- MACD
- MRK -0.25
- TGTX -0.25
- Stochastic Oscillator
- MRK 5.90
- TGTX 33.77
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.